The new magnetic resonance imaging (MRI) device reportedly offers deep learning technologies and advanced processing of whole-body images in a cost-effective and lightweight model.
An emerging whole body magnetic resonance imaging (MRI) system may provide enhanced imaging capabilities with lower costs and energy consumption in comparison to conventional whole body MRI scanners.
The MAGNETOM Free.Star MRI scanner, recently cleared by the Food and Drug Administration (FDA), offers targeted denoising and high-resolution scans through artificial intelligence (AI)-powered Deep Resolve algorithms, according to Siemens Healthineers, the manufacturer of the MRI system.
Noting that the MAGNETOM Free.Star device is the smallest and most lightweight whole-body MRI system it has manufactured, the company emphasized that it requires less than one liter of liquid helium and no quench pipe. Siemens Healthineers said the reduced energy consumption can lead to a greater than 30 percent reduction in lifecycle costs of the device in comparison to other MRI devices.
Siemens Healthineers noted another aspect of the modality is the myExam Companion, which enhances exam efficiency through AI.
“The MAGNETOM Free.Star is further proof of our steadfast commitment to providing customers with MRI scanners that are more cost-effective, more easily operable, and more easily sited for installation at a wide variety of healthcare institutions across the United States,” noted Jane Kilkenny, the vice president of MR Business Management at Siemens Healthineers.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.